Literature DB >> 9603469

Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs.

T Ishigami1, C A White, M P Pender.   

Abstract

The administration of soluble myelin proteins is an effective way of down-regulating the inflammation in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. To shed more light on the mechanism of this antigen-specific therapy, we determined the effect of the intraperitoneal (i.p.) injection of soluble myelin basic protein (MBP) on Tcell apoptosis in the CNS and peripheral lymphoid organs of Lewis rats with EAE induced by inoculation with MBP and complete Freund's adjuvant. In particular we assessed the level of apoptosis of Vbeta8.2+ Tcells, which constitute the predominant encephalitogenic MBP-reactive T cell population in the Lewis rat. The daily i.p. injection of MBP for 3 days from the onset of neurological signs inhibited the further development of neurological signs of EAE. Using two-color flow cytometry we found that a single i.p. injection of MBP increased the level of apoptosis of the Vbeta8.2+ T cell population in the CNS to 26.2% compared to 7.4% in saline-treated rats and 7.6% in ovalbumin-treated rats. In contrast, treatment with MBP did not increase the level of apoptosis of the Vbeta8.2+ population in the popliteal lymph node draining the inoculation site (1.4%) or in the spleen (1.6%) above that occurring in saline-treated rats (1.6% and 1.1%, respectively). Limiting dilution analysis revealed that the frequency of T cells reactive to the major encephalitogenic epitope, MBP72-89, was decreased in the CNS but not in the popliteal lymph node by this treatment. Three-color flow cytometry in MBP-treated rats demonstrated that CNS Vbeta8.2+ T cells expressing Fas (CD95) and Fas ligand were highly vulnerable to apoptosis compared to Vbeta8.2+ Tcells not expressing these proteins. We conclude that the i.p. injection of MBP increases the spontaneously occurring Fas-mediated activation-induced apoptosis of autoreactive T cells in the CNS in EAE and that this contributes to the therapeutic effect of the injection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603469     DOI: 10.1002/(SICI)1521-4141(199805)28:05<1626::AID-IMMU1626>3.0.CO;2-B

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells.

Authors:  Trygve Holmøy; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

Review 2.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

3.  Soluble peptide treatment reverses CD8 T-cell-induced disease in a mouse model of spontaneous tissue-selective autoimmunity.

Authors:  So Yeon Paek; Fumi Miyagawa; Hong Zhang; Jay T Linton; Shelley B Hoover; R Mark Simpson; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2011-11-17       Impact factor: 8.551

4.  Anamnestic recall of stroke-related deficits: an animal model.

Authors:  Dannielle Zierath; Jessica Hadwin; Anna Savos; Kelly T Carter; Allison Kunze; Kyra J Becker
Journal:  Stroke       Date:  2010-10-14       Impact factor: 7.914

5.  Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein.

Authors:  Trygve Holmøy; Espen Østhagen Kvale; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

6.  Characterizing a soluble survival signal for activated lymphocytes from CD14+ cells.

Authors:  Xiaolei Tang; David E Yocum; David DeJonghe; Kathy Nordensson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

7.  Blood-borne soluble protein antigen intensifies T cell activation in autoimmune CNS lesions and exacerbates clinical disease.

Authors:  F Odoardi; N Kawakami; W E F Klinkert; H Wekerle; A Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

Review 8.  Fas ligand-mediated apoptosis in degenerative disorders of the brain.

Authors:  Douglas W Ethell; Lillian A Buhler
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

9.  Programmed Death Ligand-1 on Microglia Regulates Th1 Differentiation via Nitric Oxide in Experimental Autoimmune Encephalomyelitis.

Authors:  Jingxia Hu; Hao He; Zhengang Yang; Guangming Zhu; Li Kang; Xiuli Jing; Hai Lu; Wengang Song; Bo Bai; Hua Tang
Journal:  Neurosci Bull       Date:  2016-01-14       Impact factor: 5.203

Review 10.  Fas ligand-mediated apoptosis in degenerative disorders of the brain.

Authors:  Douglas W Ethell; Lillian A Buhler
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.